Vericel Corporation

VCEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-17.3M $-19.6M $-16.3M $-19.9M $-15.6M $-29.5M $-19.7M $-14.6M
Depreciation & Amortization $1.6M $1.9M $1.6M $752.0K $489.0K $649.0K $647.0K $592.0K
Depreciation $1.6M $1.6M $1.3M $800.0K — — — —
Amortization — $300.0K $300.0K $200.0K $0 — — —
Stock-Based Compensation $2.7M $2.5M $2.7M $839.0K $926.0K $3.6M $3.7M $710.0K
Net Cash from Operating Activities $-13.2M $-19.9M $-13.3M $-25.4M $-19.9M $-29.5M $-24.5M $-15.1M
Investing Activities
Capital Expenditures $1.5M $1.4M $2.4M $829.0K $40.0K $273.0K $1.0M $120.0K
Business Acquisitions — $0 $0 $1.5M $0 — — —
Net Cash from Investing Activities $-1.5M $-1.4M $-2.4M — — — — —
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $18.6M $29.7M $-24.0K — — — — —
Net Change in Cash $3.9M — — — — — — —
Free Cash Flow $-14.7M $-21.3M $-15.8M $-26.2M $-20.0M $-29.8M $-25.5M $-15.2M
← Newer Page 2 of 3 Older →